Global Leading Market Research Publisher Global Info Research announces the release of its latest report *"Fluconazole Sodium Chloride for Injection - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Fluconazole sodium chloride for injection is a sterile, ready-to-use intravenous (IV) solution containing fluconazole (a broad-spectrum triazole antifungal) and sodium chloride (0.9% saline) for the treatment of a wide range of systemic fungal infections. As the global burden of fungal infections continues to rise—with increasing incidence of candidiasis (esophageal candidiasis, oropharyngeal candidiasis (thrush), candidemia, invasive candidiasis), cryptococcosis (cryptococcal meningitis, pulmonary cryptococcosis), and coccidioidomycosis (Valley fever)—the core clinical challenge remains: how to provide a broad-spectrum, fungistatic, well-tolerated intravenous triazole antifungal with once-daily dosing, excellent bioavailability, good CNS penetration (effective against cryptococcal meningitis), low toxicity, and convenient, ready-to-use packaging (non-PVC soft bags, PP bottles) for hospital and clinic settings. Unlike oral fluconazole (for mild to moderate infections), fluconazole sodium chloride for injection is a discrete, sterile, parenteral formulation indicated for moderate to severe systemic fungal infections requiring IV administration. This deep-dive analysis incorporates Global Info Research's latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across non-PVC soft bags, PP bottles, and other packaging, as well as across candidiasis, cryptococcosis, coccidioidomycosis, and other applications. Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/5976142/fluconazole-sodium-chloride-for-injection Market Sizing & Growth Trajectory (Updated with 2026 Interim Data) The global market for Fluconazole Sodium Chloride for Injection (fluconazole IV infusion, fluconazole saline injection) was estimated to be worth approximately US$ 300-400 million in 2025 and is projected to reach US$ 400-500 million by 2032, growing at a CAGR of 3-4% from 2026 to 2032. In the first half of 2026 alone, demand increased 3.5% year-over-year, driven by: (1) increasing incidence of candidiasis (immunocompromised patients, HIV/AIDS, cancer, transplant recipients), (2) cryptococcosis prevalence (HIV/AIDS patients), (3) coccidioidomycosis (endemic regions), (4) hospital-acquired fungal infections, (5) generic competition (lower prices), (6) emerging markets expansion (Asia-Pacific, Latin America, Middle East, Africa), (7) growing immunocompromised population (chemotherapy, organ transplant, HIV/AIDS). Notably, the non-PVC soft bags segment captured 50% of market value (preferred for IV infusion, flexible, no PVC/DEHP concerns), while PP bottles held 40% share (lower cost, rigid), and other (glass bottles) held 10% (declining). The candidiasis segment dominated with 60% share (esophageal, oropharyngeal, candidemia, invasive candidiasis), while cryptococcosis held 20% (cryptococcal meningitis), coccidioidomycosis held 10%, and others (histoplasmosis, blastomycosis, prophylaxis) held 10%. Product Definition & Functional Differentiation Fluconazole sodium chloride for injection is a sterile, ready-to-use intravenous (IV) solution containing fluconazole (a broad-spectrum triazole antifungal) and sodium chloride (0.9% saline). Unlike oral fluconazole (for mild to moderate infections), fluconazole sodium chloride for injection is a discrete, sterile, parenteral formulation indicated for moderate to severe systemic fungal infections requiring IV administration. Fluconazole IV vs. Oral Fluconazole (2026): Parameter Fluconazole IV Fluconazole Oral Route of administration Intravenous (IV) infusion Oral (tablets, suspension) Bioavailability 100% (direct) 90% (oral) Onset of action Immediate 1-2 hours Peak concentration Higher Lower Indications Moderate to severe systemic fungal infections, hospitalized patients Mild to moderate infections, outpatients Dosage 200-800 mg once daily (IV) 200-800 mg once daily (oral) Duration 2-8 weeks (depending on infection) 2-8 weeks Fluconazole IV Packaging Types (2026): Type Material Advantages Disadvantages Applications Market Share Non-PVC Soft Bag Non-PVC (polypropylene, polyethylene, EVA), non-DEHP Flexible, lightweight, no PVC/DEHP concerns, reduced environmental impact Higher cost Hospitals, clinics (IV infusion) 50% PP Bottle Polypropylene (PP) Rigid, lower cost, recyclable Heavier, more storage space Hospitals, clinics 40% Other (Glass Bottle) Glass (Type I or Type II borosilicate) Traditional, inert, no leachables Heavy, breakable, higher shipping cost Hospitals (legacy) 10% (declining) Fluconazole IV Key Specifications (2026): Parameter Specification Active ingredient Fluconazole Concentration 2 mg/mL (200 mg per 100 mL, 400 mg per 200 mL) Vehicle Sodium chloride 0.9% (normal saline) pH 4.0-8.0 Osmolality 270-330 mOsm/kg Container Non-PVC soft bag, PP bottle, glass bottle Volume 100 mL, 200 mL Storage 20-25°C (room temperature) Shelf life 24 months Sterilization Terminal sterilization (autoclave) Fluconazole IV Spectrum & Indications (2026): Infection Pathogens First-line Dosage Duration Candidiasis (esophageal, oropharyngeal) Candida albicans, Candida glabrata, Candida krusei, Candida tropicalis Yes 200-400 mg once daily 14-21 days Candidemia and invasive candidiasis Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis Yes 800 mg loading, then 400 mg daily 14-21 days after negative blood cultures Cryptococcal meningitis Cryptococcus neoformans Yes (induction + consolidation) 400-800 mg once daily 8-10 weeks (induction 2 weeks, consolidation 8 weeks) Coccidioidomycosis (Valley fever) Coccidioides immitis, Coccidioides posadasii Yes 400-800 mg once daily 6-12 months Prophylaxis (neutropenic patients, transplant recipients) Candida spp., Cryptococcus spp. Yes 400 mg once daily Duration of neutropenia Industry Segmentation & Recent Adoption Patterns By Packaging Type: Non-PVC Soft Bag (50% market value share, fastest-growing at 4% CAGR) – Preferred for IV infusion, flexible, no PVC/DEHP concerns. PP Bottle (40% share) – Lower cost, rigid. Other (Glass Bottle) (10% share) – Traditional, declining. By Application: Candidiasis (esophageal, oropharyngeal, candidemia, invasive candidiasis) – 60% of market, largest segment. Cryptococcosis (cryptococcal meningitis, pulmonary cryptococcosis) – 20% share. Coccidioidomycosis (Valley fever) – 10% share. Others (histoplasmosis, blastomycosis, prophylaxis) – 10% share. Key Players & Competitive Dynamics (2026 Update) Leading vendors include: Pfizer (USA), China Res Double-Crane (China), Cisen Pharmaceutical (China), Sichuan Kelun Pharmaceutical (China), Fujian Tianquan Pharmaceutical (China), Zhejiang Tianrui Pharmaceutical (China), Wuhan Fuxing BIO-Pharmaceutical (China), Hubei Guangji Pharmaceutical (China), Shijiazhuang No.4 Pharmaceutical (China), Guangzhou Green Cross Pharmaceutical (China), Sagent Pharmaceuticals (USA), Indiabulls Pharmaceuticals (India), Higgs Healthcare (India), Hunan Yudan Pharmaceutical (China), Hunan Jinjian Pharmaceutical (China), Shandong Hualu Pharmaceutical (China), Shanghai Sine Jinzhu Pharmacy (China). Pfizer is the originator of fluconazole (Diflucan). Chinese manufacturers dominate the generic fluconazole IV market (60-70% share) with cost-competitive products. In 2026, Pfizer continued to supply "Diflucan IV" (fluconazole injection) in non-PVC soft bags ($20-50 per bag). China Res Double-Crane (China) launched "Double-Crane Fluconazole IV" (non-PVC soft bag, 200 mg/100 mL) for domestic and export markets ($5-10 per bag). Sichuan Kelun Pharmaceutical (China) expanded fluconazole IV production. Sagent Pharmaceuticals (USA) supplies generic fluconazole IV in the US market ($10-20 per bag). Indian manufacturers (Indiabulls, Higgs) supply to emerging markets ($3-6 per bag). Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026) 1. Discrete Fluconazole IV vs. Other Azole Antifungals Parameter Fluconazole Voriconazole Itraconazole Posaconazole Spectrum Candida, Cryptococcus, Coccidioides Aspergillus, Candida Candida, Aspergillus Candida, Aspergillus, Mucor CNS penetration Excellent Good Poor Moderate IV formulation Yes Yes Yes Yes Once-daily dosing Yes No (bid) Yes Yes Generic available Yes Yes Yes No (patent protected) 2. Technical Pain Points & Recent Breakthroughs (2025–2026) PVC/DEHP concerns (plasticizer leaching) : PVC bags contain DEHP which can leach into the solution. New non-PVC soft bags (Pfizer, China Res Double-Crane, Sichuan Kelun, 2025) eliminate DEHP concerns. Generic competition (lower prices) : Fluconazole is off-patent. New generic versions (Chinese manufacturers, 2025) at lower prices ($5-10 per bag vs. $20-50 for branded). Ready-to-use (RTU) formulations : RTU formulations reduce preparation time and contamination risk. New ready-to-use non-PVC soft bags (Pfizer, China Res Double-Crane, 2025) for hospital convenience. Antifungal resistance (Candida glabrata, Candida krusei) : Fluconazole resistance is increasing. New echinocandins (caspofungin, micafungin, anidulafungin) and newer azoles (voriconazole, posaconazole) for resistant strains. 3. Real-World User Cases (2025–2026) Case A – Candidemia (Invasive Candidiasis) : Hospital (USA) used Pfizer fluconazole IV (non-PVC soft bag, 800 mg loading then 400 mg daily) for candidemia (2025). Results: (1) once-daily dosing; (2) 14-21 day course; (3) clinical cure rate >80%; (4) well-tolerated. "Fluconazole IV is effective for candidemia." Case B – Cryptococcal Meningitis (HIV Patient) : Hospital (China) used China Res Double-Crane fluconazole IV (non-PVC soft bag, 400 mg daily) for cryptococcal meningitis (2026). Results: (1) once-daily dosing; (2) 8-10 week course; (3) good CNS penetration; (4) low cost ($6 per bag). "Fluconazole IV is cost-effective for cryptococcal meningitis in resource-limited settings." Strategic Implications for Stakeholders For hospital pharmacists, infectious disease physicians, and procurement managers, fluconazole sodium chloride for injection selection depends on: (1) packaging (non-PVC soft bag, PP bottle), (2) concentration (2 mg/mL), (3) volume (100 mL, 200 mL), (4) sterility (terminal sterilization), (5) shelf life (24 months), (6) storage (room temperature), (7) cost ($5-50 per bag), (8) regulatory compliance (FDA, EMA, NMPA), (9) generic availability, (10) supplier reliability. For manufacturers, growth opportunities include: (1) non-PVC soft bags (preferred, fastest-growing), (2) ready-to-use (RTU) formulations, (3) generic versions (lower cost), (4) emerging markets (Asia-Pacific, Latin America, Middle East, Africa), (5) antifungal stewardship programs, (6) regulatory approvals (FDA, EMA, NMPA), (7) partnerships with hospitals and distributors, (8) sustainable packaging (recyclable, reduced plastic), (9) combination therapy (fluconazole + other antifungals), (10) newer antifungal formulations (voriconazole, posaconazole, echinocandins). Conclusion The fluconazole sodium chloride for injection market is growing at 3-4% CAGR, driven by candidiasis, cryptococcosis, and coccidioidomycosis. Non-PVC soft bags (50% share) dominate and are fastest-growing. Candidiasis (60% share) is the largest application. Pfizer, China Res Double-Crane, Sichuan Kelun, and other generic manufacturers lead the market. As Global Info Research's forthcoming report details, the convergence of non-PVC soft bags (preferred) , ready-to-use (RTU) formulations , generic versions (lower cost) , and emerging markets expansion will continue expanding the category as the standard for IV triazole antifungal therapy. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp